Botensilimab

Agenus presented new biomarker data at ASCO, showing botensilimab (BOT) plus balstilimab (BAL) can stratify survival in MSS mCRC and other “cold” tumors. This immunotherapy combination shows promise in overcoming resistance by potentially activating the immune response in tumors that typically don’t respond to current checkpoint inhibitors. The data suggests successful identification of biomarkers that predict patient response, paving the way for personalized treatment strategies beyond colorectal cancer.